Literature DB >> 25036956

Increased microRNA-223 in Helicobacter pylori-associated gastric cancer contributed to cancer cell proliferation and migration.

Lianjun Ma1, Yan Chen, Bin Zhang, Guifeng Liu.   

Abstract

Dysregulation of microRNA-223 (miR-223) was associated with gastric cancer (GC), in which Helicobacter pylori (H. pylori) played important roles. However, the mechanism of relationships between miR-223 and H. pylori-associated GC was largely undiscovered. Here, we found the overexpression of miR-223 was related with H. pylori positive infection in vivo and in vitro in GC by relative quantification of qRT-PCR. Upregulated miR-223 was responsible for the poorer prognosis of GC with H. pylori positive, also. The result indicated not only overexpression of miR-223 stimulated the proliferation by CCK-8 assays and colony formation of H. pylori associated GC cells, but also migration and invasion by scratch assay and transwell invasion assays in vitro. Above all, all our data declared H. pylori infection played an important role in developing GC according to overexpression of miR-223, which increased cancer cell proliferation and migration.

Entities:  

Keywords:  Helicobacter pylori; gastric cancer; microRNA-223; migration; proliferation

Mesh:

Substances:

Year:  2014        PMID: 25036956     DOI: 10.1080/09168451.2014.895661

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  17 in total

1.  Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening.

Authors:  Hui Wang; Lei Wang; Zheng Wu; Rong Sun; Haifeng Jin; Jifeng Ma; Lili Liu; Rui Ling; Jun Yi; Ling Wang; Jiefang Bian; Jianghao Chen; Nanlin Li; Shifang Yuan; Jun Yun
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  Helicobacter pylori controls NLRP3 expression by regulating hsa-miR-223-3p and IL-10 in cultured and primary human immune cells.

Authors:  Suneesh Kumar Pachathundikandi; Steffen Backert
Journal:  Innate Immun       Date:  2017-11-16       Impact factor: 2.680

Review 3.  Helicobacter pylori and microRNAs: Relation with innate immunity and progression of preneoplastic conditions.

Authors:  Diogo Libânio; Mário Dinis-Ribeiro; Pedro Pimentel-Nunes
Journal:  World J Clin Oncol       Date:  2015-10-10

4.  MicroRNA-99b promotes Helicobacter pylori-induced autophagyand suppresses carcinogenesis by targeting mTOR.

Authors:  Liu Yang; Cong Li; Yujie Jia
Journal:  Oncol Lett       Date:  2018-08-06       Impact factor: 2.967

Review 5.  Dysregulation of non-coding RNAs in gastric cancer.

Authors:  Qing Yang; Ren-Wen Zhang; Peng-Cheng Sui; Hai-Tao He; Lei Ding
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

6.  Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Jia Ma; Binbin Fang; Fanpeng Zeng; Cong Ma; Haijie Pang; Long Cheng; Ying Shi; Hui Wang; Bin Yin; Jun Xia; Zhiwei Wang
Journal:  Oncotarget       Date:  2015-01-30

7.  miR-221 and miR-222 Simultaneously Target RECK and Regulate Growth and Invasion of Gastric Cancer Cells.

Authors:  Wenneng Liu; Nian Song; Huihua Yao; Liying Zhao; Hao Liu; Guoxin Li
Journal:  Med Sci Monit       Date:  2015-09-13

8.  Inhibiting inducible miR-223 further reduces viable cells in human cancer cell lines MCF-7 and PC3 treated by celastrol.

Authors:  Lu Cao; Xue Zhang; Fanfan Cao; Ying Wang; Yufan Shen; Chunxin Yang; Georges Uzan; Bin Peng; Denghai Zhang
Journal:  BMC Cancer       Date:  2015-11-09       Impact factor: 4.430

9.  MicroRNA-223 promotes mast cell apoptosis by targeting the insulin-like growth factor 1 receptor.

Authors:  Haiyan Gao; Huan Deng; Hong Xu; Qianyuan Yang; Yao Zhou; Jiamin Zhang; Deyu Zhao; Feng Liu
Journal:  Exp Ther Med       Date:  2016-04-05       Impact factor: 2.447

10.  Prognostic value of microRNAs in gastric cancer: a meta-analysis.

Authors:  Yue Zhang; Dong-Hui Guan; Rong-Xiu Bi; Jin Xie; Chuan-Hua Yang; Yue-Hua Jiang
Journal:  Oncotarget       Date:  2017-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.